Our RNA drug platform integrates dual oligo-binders (RNA aptamers) with dual oligo-silencers (siRNA) into a single self delivering SeekR drug. The dual oligo-binders are engineered to seek out and cross link two specific cell surface receptors, which  achieves unprecedented selectivity for delivery to the right cell subtypes, and triggers highly efficient cellular internalization. Innovations in AI based molecular modeling have transformed how our scientists discover and optimize RNA oligo-binder interactions with target cell surface receptor proteins to create the next generation of RNA therapeutics.